SLEDAI-2K (SLE Disease Activity Index)
SLEDAI-2K (Gladman 2002): 24 weighted descriptors of lupus activity present at the visit or in the preceding 10 days (0–105). Tick every descriptor that is present.
Score interpretation
→ Maintenance therapy; hydroxychloroquine; 3-6 monthly review
→ Maintenance therapy; hydroxychloroquine; 3-6 monthly review
→ Consider steroids; DMARD optimisation (azathioprine, MMF); rheumatology review
→ High-dose steroids; consider biologic (belimumab, anifrolumab); organ-specific treatment (lupus nephritis: MMF or cyclophosphamide)
→ High-dose steroids; consider biologic (belimumab, anifrolumab); organ-specific treatment (lupus nephritis: MMF or cyclophosphamide)
Interpretation bands for the SLEDAI-2K. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Hydroxychloroquine · Antimalarial — Lupus / Dermatoses
- Belimumab (Cutaneous Lupus) · BLyS/BAFF Inhibitor (Anti-B-Lymphocyte Stimulator)
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.